1
|
Piccolo C, Vigorito S, Rondi E, Piperno G, Ferrari A, Pepa M, Riva G, Durante S, Conte E, Catto V, Andreini D, Carbucicchio C, Jereczek-Fossa BA, Pompilio G, Orecchia R, Cattani F. Phantom study of stereotactic radioablation for ventricular tachycardia (STRA-MI-VT) using Cyberknife Synchrony Respiratory Tracking System with a single fiducial marker. Phys Med 2022; 100:135-141. [PMID: 35816942 DOI: 10.1016/j.ejmp.2022.06.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 06/22/2022] [Accepted: 06/29/2022] [Indexed: 12/25/2022] Open
Abstract
PURPOSE Within the STRA-MI-VT phase Ib/II trial (NCT04066517), the aim of this phantom study was to explore the feasibility of Cyberknife treatments on cardiac lesions by tracking as a single marker the lead tip of an implantable cardioverter defibrillator. The residual displacement of the lesion during the tracking was studied, planning margins were found and the dosimetric accuracy of the treatment was checked. MATERIALS AND METHODS A lead was inserted into a phantom (EasyCube phantom, Sun Nuclear Co, USA) and then placed on the translating ExacTrac Gating System (BrainLAB AG, Germany). The phantom was rotated, a virtual lesion was identified and its displacement during the tracking was studied. Two plans were compared, calculated on the unrotated volume and on the envelope of the unrotated and the rotated volumes. The plans were delivered using the Cyberknife System (Accuray Inc, USA) and their dosimetric accuracy verified by gamma analysis with gafchromic films. RESULTS The residual margin increases enhancing the distance between the lead and the lesion. It is 4 mm for distance 0 cm and 5 mm for distance 5 cm. The coverage is reduced by 3.8% (interquartile range 2.5%-4.7%) when the dose is prescribed on the unrotated volume. All treatment plans are accurate and 3% 3 mm gamma analysis results are greater than 94%. CONCLUSIONS Results showed that tracking with a single marker is feasible considering adequate residual planning margins. The volumes could be further reduced by using additional markers, for example by placing them on the patient's skin.
Collapse
Affiliation(s)
- C Piccolo
- Unit of Medical Physics, IEO European Institute of Oncology, IRCCS, Milan, Italy.
| | - S Vigorito
- Unit of Medical Physics, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - E Rondi
- Unit of Medical Physics, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - G Piperno
- Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - A Ferrari
- Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - M Pepa
- Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - G Riva
- Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - S Durante
- Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy
| | - E Conte
- Cardiovascular Imaging Department, Centro Cardiologico Monzino IRCCS, Milan, Italy; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy
| | - V Catto
- Department of Clinical Electrophysiology and Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Milan, Italy; Department of Electronics, Information and Biomedical Engineering, Politecnico di Milano, Milan, Italy
| | - D Andreini
- Cardiovascular Imaging Department, Centro Cardiologico Monzino IRCCS, Milan, Italy; Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy
| | - C Carbucicchio
- Department of Clinical Electrophysiology and Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Milan, Italy
| | - B A Jereczek-Fossa
- Division of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - G Pompilio
- Scientific Directorate, Centro Cardiologico Monzino IRCCS, Milan, Italy; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - R Orecchia
- Scientific Directorate, IEO European Institute of Oncology IRCCS, Milan, Italy
| | - F Cattani
- Unit of Medical Physics, IEO European Institute of Oncology, IRCCS, Milan, Italy
| |
Collapse
|
2
|
Alterio D, Vigorito S, Emiro F, Vincini M, Ferrari A, Marani S, Pepa M, Zaffaroni M, Fodor C, Volpe S, Marvaso G, Bergamaschi L, Pedone C, Franzetti J, Zorzi S, Tagliabue M, Ansarin M, Jereczek-Fossa B. PO-1114 Intensity Modulated Radiotherapy (IMRT) after conservative surgery for supraglottic tumours. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03078-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Dicuonzo S, Colombo F, Bergamaschi L, Piperno G, Ferrari A, Leonardi M, Zaffaroni M, Zerella M, Rojas D, Gerardi M, Morra A, Rondi E, Vigorito S, Cattani F, Orecchia R, Jereczek-Fossa B, Frassoni S, Bagnardi V. PO-1228 Radiosurgery in her2-breast cancer brain metastasis:local control and overall survival in 32 women. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03192-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Piccolo C, Vigorito S, Rondi E, Piperno G, Ferrari A, Pepa M, Conte E, Catto V, Andreini D, Carbucicchio C, Jereczek-Fossa B, Cattani F. Phantom study of stereotactic radioablation treatments for ventricular tachycardia (STRA-MI-VT) using Cyberknife synchrony respiratory tracking system with a single fiducial marker. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00164-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
5
|
Piccolo C, Vigorito S, Rondi E, Piperno G, Ferrari A, Pepa M, Conte E, Catto V, Andreini D, Carbucicchio C, Jereczek-Fossa B, Cattani F. PO-1725 Phantom study of Cyberknife Synchrony cardiac treatments with a single fiducial marker. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08176-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Marvaso G, Corrao G, Oneta O, Gugliandolo S, Pepa M, Cecconi A, Gandini S, Piperno G, Cossu Rocca M, Verri E, Aurilio G, Corso F, Cullurà D, Rondi E, Vigorito S, Nolè F, Orecchia R, Jereczek-Fossa B. PO-1218: Oligo Metastatic renal cell carcinoma: SBRT, if, when and how? Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01236-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Leonardi M, Cattani F, Pepa M, Luraschi R, Vigorito S, Gugliandolo S, Ciardo D, Orecchia R, Jereczek-Fossa B. PO-0979: Variability of axillary nodal CTV contouring in breast cancer (PART I - geometric evaluation). Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00997-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Leonardi M, Cattani F, Pepa M, Luraschi R, Vigorito S, Gugliandolo S, Ciardo D, Orecchia R, Jereczek-Fossa B. PO-0981: Variability of axillary nodal CTV contouring in breast cancer (PART II – dosimetric impact). Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00999-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Durante S, Corrao G, Marvaso G, Piperno G, Colombo F, Gugliandolo S, Rondi E, Vigorito S, Frassoni S, Bagnardi V, Fodor C, Spaggiari L, De Marinis F, Orecchia R, Jereczek-Fossa B. PO-1023: Impact of biological features in radiosurgery for Brain metastases from Non Small Cell Lung Cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01040-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Francia CM, Marvaso G, Piperno G, Gandini S, Ferrari A, Zerella MA, Arculeo S, Sibio D, Fodor C, Pepa M, Trivellato S, Rondi E, Vigorito S, Cattani F, Spaggiari L, De Marinis F, Orecchia R, Ciardo D, Jereczek-Fossa BA. Lung optimized treatment with CyberKnife® in inoperable lung cancer patients: feasibility analysis of a mono-institutional 115 patient series. Neoplasma 2020; 67:684-691. [PMID: 32182088 DOI: 10.4149/neo_2020_190717n645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Accepted: 09/29/2019] [Indexed: 11/08/2022]
Abstract
CyberKnife® Lung Optimized Treatment (LOT) allows the treatment of lung cancer without invasive fiducial implantation. The aim of this retrospective analysis was to evaluate the feasibility, toxicity and clinical outcome. One hundred fifteen patients (124 lesions) were treated with CyberKnife® using LOT. The median age was 72.6 years (range 31.8-90.3). From 124 treated lesions, 52 were with histopathological confirmation (41 primitive pulmonary cancers, 8 pulmonary metastases) and 72 as untyped tumors. For 5 patients (6 lesions) treatment was an in-field re-irradiation. Concomitant therapy was administered in 7 patients. Zero-View tracking was applied in 69 patients, 1-View in 33 patients, 2-View in 22 patients. The median total dose was 45 Gy (range 18-54), median dose/fraction was 15 Gy (range 4-18) with a median prescription isodose of 80% (range 68-85). The median planning target volume (PTV) was 25 cm3 (range 3-195). The median follow-up was 20 months (range 7-47). Thirty-seven patients (32%) were alive with no evidence of disease, 39 patients (34%) were alive with clinically evident disease, and 38 patients (33%) died of the disease. The 1- and 2-year overall survival (OS) rate was 83% and 61%. The median time to progression was 19 months (95% confidence interval: 11-19 months), 1- and 2-year progression-free survival (PFS) rates were 62% and 41%, respectively. Smaller PTV was significantly associated with better OS, PFS and in-field PFS in univariate and multivariate analyses. Acute toxicity was observed in 36 patients (41%). Late toxicity was registered in 25 patients (29%). G3 late toxicity was observed in one patient (1.1%). Our data suggest that fiducial less-stereotactic body radiation therapy (SBRT) is a feasible, well-tolerated and potentially effective treatment with high compliance in the setting of inoperable patients due to concomitant disease or previous treatments.
Collapse
Affiliation(s)
- C Maria Francia
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - G Marvaso
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - G Piperno
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - S Gandini
- Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - A Ferrari
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - M Alessia Zerella
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - S Arculeo
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - D Sibio
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - C Fodor
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - M Pepa
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - S Trivellato
- Unit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - E Rondi
- Unit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - S Vigorito
- Unit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - F Cattani
- Unit of Medical Physics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - L Spaggiari
- Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.,Division of Thoracic Surgery, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - F De Marinis
- Division of Thoracic Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - R Orecchia
- Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.,Scientific Directorate, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - D Ciardo
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy
| | - B Alicja Jereczek-Fossa
- Department of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| |
Collapse
|
11
|
Trivellato S, Rondi E, Vigorito S, Miglietta E, Castellini F, Piperno G, Ferrari A, Jereczek-Fossa B, Cattani F. PO-0905 Validation of a 4D Monte Carlo optimization and planning feature for CyberKnife lung treatment. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31325-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Riva G, Ferrari A, Durante S, Ciardo D, Piperno G, Leonardi M, Vigorito S, Rondi E, Orecchia R, Jereczek-Fossa B. EP-1212 Clinical outcome in brain metastases from breast cancer treated with stereotactic radiotherapy. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31632-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Trivellato S, Rondi E, Vigorito S, Miglietta E, Castellini F, Piperno G, Ferrari A, Jereczek-Fossa B, Cattani F. OC-0094 Retrospective evaluation of motion effects in robotic radiosurgery treatments of lung cancer. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30514-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
14
|
Volpe S, Bagicalupo A, Alterio D, Belgioia L, Ferrari A, Zurlo V, Santomauro V, Marvaso G, Montesano M, Augugliaro M, Turturici I, Vigorito S, Corvò R, Jereczek-Fossa B. PO-147 Functional outcome of postoperative IMRT after laryngeal conservative surgery. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30313-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Augugliaro M, Marvaso G, Ciardo D, Zerini D, Riva G, Rondi E, Vigorito S, Comi S, Cobelli OD, Orecchia R, Jereczek-Fossa BA. Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy? Neoplasma 2019; 66:160-165. [DOI: 10.4149/neo_2018_180522n333] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 07/24/2018] [Indexed: 11/08/2022]
|
16
|
Savini A, Fusella M, Esposito M, Ardu V, Benecchi G, Bergantin A, Borzi G, Bresciani S, Cagni E, Carbonini C, Casati M, Clemente S, Consorti R, Cora S, DeMartin E, ElGawhary R, Falco M, Fedele D, Fiandra C, Frassanito M, Garibaldi C, Gasperi G, Giglioli F, Guidi G, Ielo I, Landoni V, Magi S, Malatesta T, Marino C, Masi L, Moretti E, Naccarato S, Nardiello B, Nigro R, Pastore G, Presello M, Ravaglia V, Russo S, Strigari L, Strolin S, Talamonti C, Vaiano A, Vigorito S, Villaggi E, Stasi M, Mancosu P. 161. A crowd-knowledge-based analysis of DVHs in SBRT: First steps towards a national virtual audit. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
17
|
Volpe S, Jereczek-Fossa BA, Zerini D, Rojas DP, Fodor C, Vavassori A, Romanelli P, Vigorito S, Rondi E, Comi S, Cambria R, Cattani F, Dicuonzo S, De Marco P, Beltramo G, Musi G, De Cobelli O, Marvaso G, Orecchia R. Case series on multiple prostate re-irradiation for locally recurrent prostate cancer: something ventured, something gained. Neoplasma 2018; 66:308-314. [PMID: 30509110 DOI: 10.4149/neo_2018_180723n520] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Accepted: 10/16/2018] [Indexed: 11/08/2022]
Abstract
The aim is to present the technical feasibility and efficacy of multiple re-irradiation (re-EBRT) for local recurrence of prostate cancer (PCa) using retrospective analysis of an updated series of patients who received ablative re-EBRT with stereotactic image-guided technique for isolated local recurrence of PCa. Eight patients received three RT courses (2 re-RTs); of those 2 received 4 RT courses (3 re-RTs). Local relapse in the prostate was assessed by multiparametric magnetic resonance and/ or choline positron emission tomography. Before treatment planning, all patients had been evaluated for late toxicity from previous RT according to RTOG/EORTC. Biochemical control was assessed according to Phoenix definition. Mean age at the third RT course was 68 (standard deviation, SD: 7.2); all patients had a good performance status. At diagnosis, four cases were classified as high risk PCa, three as intermediate and one as low per NCCN 2017. Biochemical progression free interval after first and second RT-course were 74 (IQR: 59.3-133.6) months and 33 (IQR: 20.8-53.1) months, respectively. Biochemical and radiological response was registered in all patients. At present, seven out of eight patients are disease free. Overall toxicity profile was good; no severe acute or late genitourinary or gastrointestinal events were recorded. Multiple RT courses with high precision technology and image guidance can be proposed as a possible salvage therapy for locally recurrent, low-burden PCa recurrence in adequately selected patients. Deeper understanding of radiobiological effects of hypofractionation and larger series of patients are warranted to fully evaluate the applicability of multiple RT courses in the setting of locally recurrent PCa.
Collapse
Affiliation(s)
- S Volpe
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - B Alicja Jereczek-Fossa
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - D Zerini
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
| | - D Patricia Rojas
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - C Fodor
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
| | - A Vavassori
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
| | - P Romanelli
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
| | - S Vigorito
- Department of Medical Physics, European Institute of Oncology, Milan, Italy
| | - E Rondi
- Department of Medical Physics, European Institute of Oncology, Milan, Italy
| | - S Comi
- Department of Medical Physics, European Institute of Oncology, Milan, Italy
| | - R Cambria
- Department of Medical Physics, European Institute of Oncology, Milan, Italy
| | - F Cattani
- Department of Medical Physics, European Institute of Oncology, Milan, Italy
| | - S Dicuonzo
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - P De Marco
- Department of Medical Physics, European Institute of Oncology, Milan, Italy
| | | | - G Musi
- Department of Urology, European Institute of Oncology, Milan, Italy
| | - O De Cobelli
- Department of Urology, European Institute of Oncology, Milan, Italy
| | - G Marvaso
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
| | - R Orecchia
- Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.,Scientific Directorate, European Institute of Oncology, Milan, Italy
| |
Collapse
|
18
|
Volpe S, Jereczek Fossa B, Zerini D, Rojas D, Fodor C, Vavassori A, Romanelli P, Vigorito S, Rondi E, Comi S, Cambria R, Cattani F, Di Cuonzo S, De Marco P, Beltramo G, Musi G, De Cobelli O, Marvaso G, Orecchia R. EP-1555: Multiple re-irradiation for locally recurrent prostate cancer: proof of concept and clinical outcome. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31864-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Dell'Acqua V, Kobiela J, Kraja F, Leonardi MC, Surgo A, Zerella MA, Arculeo S, Fodor C, Ricotti R, Zampino MG, Ravenda S, Spinoglio G, Biffi R, Bazani A, Luraschi R, Vigorito S, Spychalski P, Orecchia R, Glynne-Jones R, Jereczek-Fossa BA. Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT. Med Oncol 2018; 35:59. [PMID: 29594584 DOI: 10.1007/s12032-018-1118-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Accepted: 03/22/2018] [Indexed: 12/16/2022]
Abstract
Intensity-modulated radiotherapy (IMRT) is considered the preferred option in squamous cell canal cancer (SCAC), delivering high doses to tumor volumes while minimizing dose to surrounding normal tissues. IMRT has steep dose gradients, but the technique is more demanding as deep understanding of target structures is required. To evaluate genital marginal failure in a cohort of patients with non-metastatic SCAC treated either with IMRT or 3DCRT and concurrent chemotherapy, 117 patients with SCAC were evaluated: 64 and 53 patients were treated with IMRT and 3DCRT techniques, respectively. All patients underwent clinical and radiological examination during their follow-up. Tumor response was evaluated with response evaluation criteria in solid tumors v1.1 guideline on regular basis. All patients' data were analyzed, and patients with marginal failure were identified. Concomitant chemotherapy was administered in 97 and 77.4% of patients in the IMRT and 3DCRT groups, respectively. In the IMRT group, the median follow-up was 25 months (range 6-78). Progressive disease was registered in 15.6% of patients; infield recurrence, distant recurrence and both infield recurrence and distant recurrence were identified in 5, 4 and 1 patient, respectively. Two out of 64 patients (3.1%) had marginal failures, localized at vagina/recto-vaginal septum and left perineal region. In the 3DCRT group, the median follow-up was 71.3 months (range 6-194 months). Two out of 53 patients (3.8%) had marginal failures, localized at recto-vaginal septum and perigenital structures. The rate of marginal failures was comparable in IMRT and 3DCRT groups (χ2 test p = 0.85). In this series, the use of IMRT for the treatment of SCAC did not increase the rate of marginal failures offering improved dose conformity to the target. Dose constraints should be applied with caution-particularly in females with involvement of the vagina or the vaginal septum.
Collapse
Affiliation(s)
- V Dell'Acqua
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
| | - J Kobiela
- Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdańsk, Poland
| | - F Kraja
- Division of Oncology, University Hospital Centre "Mother Theresa", Tirana, Albania
| | - M C Leonardi
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy.
| | - A Surgo
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
| | - M A Zerella
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - S Arculeo
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - C Fodor
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
| | - R Ricotti
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
| | - M G Zampino
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy
| | - S Ravenda
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy
| | | | - R Biffi
- Unit of Peritoneal Cancer Surgery, European Institute of Oncology, Milan, Italy
| | - A Bazani
- Unit of Medical Physics, European Institute of Oncology, Milan, Italy
| | - R Luraschi
- Unit of Medical Physics, European Institute of Oncology, Milan, Italy
| | - S Vigorito
- Unit of Medical Physics, European Institute of Oncology, Milan, Italy
| | - P Spychalski
- Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, Gdańsk, Poland
| | - R Orecchia
- Scientific Directorate, European Institute of Oncology, Milan, Italy
| | - R Glynne-Jones
- Mount Vernon Centre for Cancer Treatment, Northwood, Middlesex, HA6 2RN, UK
| | - B A Jereczek-Fossa
- Department of Radiotherapy, European Institute of Oncology, Milan, Italy
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| |
Collapse
|
20
|
Russo S, Masi L, Dicarolo P, Doro R, De Martin E, Fumagalli M, Martinotti A, Bergantin A, Rondi E, Vigorito S, Mancosu P. PO-0778: New Razor silicon diode for Cyber Knife small beam relative dosimetry: a multi-site evaluation. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31215-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
21
|
Riva G, Augugliaro M, Piperno G, Ferrari A, Rondi E, Vigorito S, Orecchia R, Jereczek-Fossa B. EP-1395: CyberKnife treatment of intraorbital metastases: a single center experience on 24 lesions. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31830-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
22
|
Talamonti C, Russo S, Barone TL, Benecchi G, Borzi G, Bresciani S, Cagni E, Carbonino C, Casale M, Clemente S, Consorti R, D’Alessio V, Dicastro E, Donofrio G, Falco M, Fedele D, Fiandra C, Frassanito C, Gasperi C, Giglioli F, Iervolino C, Infusino E, Linsalata S, Loi G, Lorenzini E, Marino C, Martinotti S, Masi L, Menghi E, Miceli R, Moretti E, Nardiello B, Nigro R, Pastore G, Pressello M, Pimpinella M, Raza G, Rosica F, Ruggeri R, Spiazzi L, Stasi M, Strigari L, Tremolada V, Vaiano A, Vigorito S, Villaggi E, Vittorini F, Mancosu P. Small beam dosimetry: A multi-center multi-detector italian project. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.07.291] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
23
|
Mastella E, Vigorito S, Rondi E, Piperno G, Ferrari A, Strata E, Rozza D, Jereczek-Fossa BA, Cattani F. Validation of a pretreatment delivery quality assurance method for the CyberKnife Synchrony system. Med Phys 2016; 43:4565. [DOI: 10.1118/1.4955437] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
24
|
Loi G, Fusella M, Lanzi E, Fiandra C, Orlani G, Lucio F, Strolin S, Gino E, Mezzenga E, Roggio A, Cagni E, Vigorito S. TU-H-CAMPUS-JeP1-03: Results From a Multi Institution Study On Image Quality Impact in Deformable Image Registration. Med Phys 2016. [DOI: 10.1118/1.4957671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
25
|
Russo S, Masi L, Bergantin A, De Martin E, Doro R, Frassanito C, Fumagalli M, Martinotti A, Rondi E, Vigorito S, Mancosu P. EP-1580: CyberKnife multi-site small beam dosimetry with a new plastic scintillator detector. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32830-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Mastella E, Vigorito S, Rondi E, Piperno G, Ferrari A, Strata E, Rozza D, Jereczek-Fossa B, Cattani F. PO-0803: Validation of a pre-treatment delivery quality assurance method for the CyberKnife Synchrony System. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32053-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
27
|
Cecconi A, Piperno G, Ferrari A, Rondi E, Vigorito S, Zerini D, Cattani F, Nolè F, De Cobelli O, Jereczek-Fossa B, Orecchia R. EP-1389: Stereotactic radiotherapy for oligometastatic patients with renal cell carcinoma. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32639-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Masi L, Russo S, Demartin E, Doro R, Frassanito C, Fumagalli M, Marinelli M, Martinotti A, Pimpinella M, Verona-Rinati G, Rondi E, Vigorito S, Vite C, Mancosu P. CyberKnife beam output factor measurements: A multi-site, multi-detector study. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.01.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
29
|
Mastella E, Vigorito S, Rondi E, Piperno G, Ferrari A, Strata E, Rozza D, Jereczek-Fossa B, Cattani F. Verification of the geometric and dosimetric accuracy of the CyberKnife synchrony system. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.01.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
30
|
Cremonesi M, Alterio D, Garibaldi C, Ferrari A, Botta F, Ferrari M, Vigorito S, Rondi E, Cattani F, Rocca MC, Strigari L, Pedicini P, Jereczek-Fosa B, Orecchia R. Combined RT and epidermal growth factor receptor inhibitor monoclonal antibody-MoAb-EGFr treatment of head and neck cancer (HNC): Radiobiological model for FAMOSO. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.01.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
31
|
Masi L, Russo S, De Martin E, Frassanito C, Fumagalli M, Martinotti A, Rondi E, Vigorito S, Vite C, Redaelli I, Marino C, Fiandra C, Clemente S, Strigari L, Esposito M, Giglioli F, Stasi M, Begnozzi L, Verona Rinati G, Marinelli M, Pimpinella M, Mancosu P. PO-0839: Synthetic diamond detector for CyberKnife beam output measurements: a multi-site study. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40831-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Cambria R, Cattani F, Jereczek-Fossa BA, Pansini F, Ciardo D, Vigorito S, Russo S, Zerini D, Cozzi L, Orecchia R. Planning study to compare dynamic and rapid arc techniques for postprostatectomy radiotherapy of prostate cancer. Strahlenther Onkol 2014; 190:569-74. [PMID: 24557057 DOI: 10.1007/s00066-014-0601-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2013] [Accepted: 11/18/2013] [Indexed: 11/28/2022]
Abstract
PURPOSE To compare our standard technique for postprostatectomy radiotherapy of prostate cancer, i.e. using two lateral conformal dynamic arcs with volumetric-modulated arc therapy (VMAT) performed with the RapidArc(®) (Varian Medical Systems, Palo Alto, CA, USA). The plans were referred to as DA and RA, respectively. MATERIALS AND METHODS The treatment plans of 44 patients receiving adjuvant/salvage radiotherapy in the first months of 2010 were compared. In all cases, the prescribed total dose was 66-68.2 Gy (2.2 Gy per fraction). Both DA and RA plans were optimized in terms of dose coverage and constraints. RESULTS Small differences between the techniques were observed for planning target volume (PTV) dose distribution, whereas significant differences in sparing of organs at risk (OARs) were recorded (p < 0.0001). The OAR values (median; 95 % confidence interval, CI) were: rectum: D30 % = 60.7 Gy (59.40-62.04 Gy) and 48.2 Gy (46.40-52.72 Gy), D60 % = 34.1 Gy (28.50-38.92 Gy) and 27.7 Gy (21.80-31.51 Gy); bladder: D30 % = 57.3 Gy (45.83-64.53 Gy) and 46.4 Gy (33.23-61.48 Gy), D50 % = 16.4 Gy (11.89-42.38 Gy) and 17.2 Gy (10.97-27.90 Gy), for DA and RA, respectively. Treatment times were very similar, whereas the monitor units (MU) were 550 ± 29 versus 277 ± 3 for RA and DA, respectively. CONCLUSION Dose-volume histograms (DVHs) show improvements in OAR sparing with RA. However, the RA technique is associated with almost double the number of MUs compared to DA. Regarding the PTV, DA is slightly superior in terms of D2 % and dose homogeneity. On the whole, the results suggest that RA be the favorable technique.
Collapse
Affiliation(s)
- R Cambria
- Department of Medical Physics, Istituto Europeo di Oncologia, via Ripamonti 435, 20141, Milan, Italy,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Jereczek-Fossa B, Pobbiati C, Santoro L, Fodor C, Fanti P, Vigorito S, Baroni G, Zerini D, De Cobelli O, Orecchia R. Prostate positioning using cone-beam computer tomography based on manual soft-tissue registration. Strahlenther Onkol 2013; 190:81-7. [DOI: 10.1007/s00066-013-0387-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2012] [Accepted: 05/22/2013] [Indexed: 11/29/2022]
|
34
|
Rondi E, Vigorito S, Bazani A, Mastella E, Russo S, Piperno G, Ferrari A, Rozza D, Castellini F, Orecchia R. EP-1162: Validation of a pre treatment specific patient QA method for Cyberknife. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33468-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
35
|
Lazzari R, Cecconi A, Dell'Acqua V, Vavassori A, Rondi E, Vigorito S, Cattani F, Fodor C, Jereczek-Fossa B, Orecchia R. 807 poster VOLUMETRIC MODULATED ARC THERAPY WITH RAPIDARC (RA-IMRT) FOR GYNAECOLOGICAL MALIGNANCIES. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)70929-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Lazzari R, Cecconi A, Dell'Acqua V, Vavassori A, Travaini L, Rondi E, Vigorito S, Cattani F, Fodor C, Jereczek-Fossa B, Orecchia R. 1163 poster FDG-PET/CT FOR TARGET VOLUME DELINEATION IN THE VOLUMETRIC MODULATED ARC RADIOTHERAPY IN CERVICAL CANCER. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71285-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Cozzi L, Bignardi M, Fogliata A, Lattuada P, Mancosu P, Navarria P, Urso G, Vigorito S, Scorsetti M. Feasibility Study of Volumetric Modulated Arc Therapy for Malignant Pleural Mesothelioma Tumor. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.1629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
38
|
Mancosu P, Bignardi M, Cozzi L, Cozzi AF, Lattuada P, Navarria P, Urso G, Vigorito S, De Sanctis M, Fozza A, Scorsetti M. RE-IRRADIATION OF METASTATIC SPINAL CORD COMPRESSION RECURRENCE: FEASIBILITY STUDY USING RAPIDARC. Radiother Oncol 2009. [DOI: 10.1016/s0167-8140(12)72866-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Papadimitriou D, Perris A, Manetou A, Molfetas M, Panagiotakis N, Lyra-Georgosopoulou M, Hourdakis K, Kottou S, Tosi G, Origgi D, Vigorito S. A survey of 14 computed tomography scanners in Greece and 32 scanners in Italy. Examination frequencies, dose reference values, effective doses and doses to organs. Radiat Prot Dosimetry 2003; 104:47-53. [PMID: 12862243 DOI: 10.1093/oxfordjournals.rpd.a006162] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
A survey of examination frequencies, dose reference values, effective doses and doses to organs involving 14 scanners from Greece and 32 scanners from Italy was carried out for the years 1999 and 2000. Examination frequencies per scanner and per year were found to be 3590 for Greece and 4520 for Italy. For the types of examinations considered, CDTI(W) and DLP measurements were taken. Also scan lengths used for the same types of examinations were monitored. For the same types of examinations effective doses were calculated by two methods, and it was found that their mean values ranged from 13.1 mSv for thoracic spine to 1.6 mSv for the brain examinations. From the data of the 14 Greek laboratories, doses to organs were calculated and it was found that the thyroid receives 50.2 +/- 19.8 mGy during a cervical spine examination while the gonads receive 17.8 +/- 6.9 mGy during a routine pelvis examination.
Collapse
Affiliation(s)
- D Papadimitriou
- Medical Physics Dept, University of Athens, School of Medicine 75 M. Asias Str., 11527 Athens, Greece.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|